Town Hall
McCullough Foundation directly reanalyzed the FDA’s own data used to approve mFLUSIVA and found an extreme risk-benefit profile that is impossible to justify, by Nicolas Hulscher, MPH.
Send this to someone
A civic square for verified Americans, open to the nations of the world, its leaders & ambassadors. Reading is open to everybody. Posting, replying and voting are for members.